BACKGROUND: Tumor-associated fibroblast growth factor 23 (FGF-23)-induced hypophosphatemic rickets is a rare but known pediatric entity first described in 1959. It results from local production of phosphatonins by benign and malignant mesenchymal tumors. CASE-DIAGNOSIS/TREATMENT: We report an 8-year-old boy with tumor-associated hypophosphatemic rickets due to paraneoplastic FGF-23 secretion from a benign mesenchymal pelvic-bone tumor. Excessive FGF-23 production was visualized by immunohistochemistry in the resected tumor. Phosphate wasting stopped immediately after tumor resection. We reviewed 26 reports of pediatric patients with tumor-induced hypophosphatemic rickets; paraneoplastic FGF-23 secretion was documented in only three of them. All tumors developed inside bone, were benign in 21/26 cases, and were localized in femur/tibia (13/26), radius/ulna/humerus (7/26), pelvis (4/26), rib (1/26), and craniofacial (1/26) bones. Mean interval between onset of signs and/or symptoms and diagnosis was 34 months. CONCLUSIONS: In patients with hypophosphatemic rickets acquired beyond infancy, radiologic investigations for bone tumors need to be performed rapidly. In contrast to biochemical screening for increased circulating FGF-23 levels, immunohistochemical confirmation of FGF-23 production in resected tumor tissue can be regarded as being well established.
BACKGROUND:Tumor-associated fibroblast growth factor 23 (FGF-23)-induced hypophosphatemic rickets is a rare but known pediatric entity first described in 1959. It results from local production of phosphatonins by benign and malignant mesenchymal tumors. CASE-DIAGNOSIS/TREATMENT: We report an 8-year-old boy with tumor-associated hypophosphatemic rickets due to paraneoplasticFGF-23 secretion from a benign mesenchymal pelvic-bone tumor. Excessive FGF-23 production was visualized by immunohistochemistry in the resected tumor. Phosphate wasting stopped immediately after tumor resection. We reviewed 26 reports of pediatric patients with tumor-induced hypophosphatemic rickets; paraneoplasticFGF-23 secretion was documented in only three of them. All tumors developed inside bone, were benign in 21/26 cases, and were localized in femur/tibia (13/26), radius/ulna/humerus (7/26), pelvis (4/26), rib (1/26), and craniofacial (1/26) bones. Mean interval between onset of signs and/or symptoms and diagnosis was 34 months. CONCLUSIONS: In patients with hypophosphatemic rickets acquired beyond infancy, radiologic investigations for bone tumors need to be performed rapidly. In contrast to biochemical screening for increased circulating FGF-23 levels, immunohistochemical confirmation of FGF-23 production in resected tumor tissue can be regarded as being well established.
Authors: Yan Jiang; Wei-bo Xia; Xiao-ping Xing; Barbara C Silva; Mei Li; Ou Wang; Hua-bing Zhang; Fang Li; Hong-li Jing; Ding-romg Zhong; Jin Jin; Peng Gao; Lian Zhou; Fang Qi; Wei Yu; John P Bilezikian; Xun-wu Meng Journal: J Bone Miner Res Date: 2012-09 Impact factor: 6.741
Authors: L M Ward; F Rauch; K E White; G Filler; M A Matzinger; M Letts; R Travers; M J Econs; F H Glorieux Journal: Bone Date: 2004-05 Impact factor: 4.398
Authors: Mouhammed Amir Habra; Camilo Jimenez; Su-Chen Eileen Huang; Gilbert J Cote; William A Murphy; Robert F Gagel; Ana O Hoff Journal: Endocr Pract Date: 2008-12 Impact factor: 3.443
Authors: Florian A Frank; Lukas Gerber; Alexander Cornelius; Daniel Baumhoer; Andreas H Krieg Journal: J Bone Oncol Date: 2022-01-29 Impact factor: 4.072